Roche reported half-year 2026 results on 23 July, with group sales of CHF 30.4 billion, up 6% at constant exchange rates (CER) and down 2% in Swiss francs after a sharp appreciation of the currency. Core operating profit reached CHF 11.9 billion, up 10% at CER, and the group reaffirmed its full-year outlook of mid single digit sales growth and high single digit core EPS growth at CER.

The Diagnostics division came in at CHF 6,735 million, up 3% at CER and down 3% in CHF. Stripping out the effect of China healthcare pricing reform, the division grew 6% at CER, in line with the Pharmaceuticals top line. That gap between headline and ex-China growth is the number analytics investors have been watching since Roche flagged pricing reform as a multi-quarter headwind in 2025.

For readers who track process and clinical analytics vendors alongside each other, the print offers a clean data point on end-market demand outside of China and on where the drag is concentrated by customer area.

Diagnostics division: growth by customer area

Roche now reports Diagnostics by four customer areas rather than legacy business units. The H1 2026 split in the group’s half-year materials:

  • Core Lab: CHF 3,756 million
  • Molecular Lab: CHF 1,196 million
  • Near Patient Care: CHF 909 million
  • Pathology Lab: CHF 874 million

Core Lab remains the anchor of the division and captured most of the immunodiagnostics volume that management called out as a driver. Molecular Lab was flagged separately for growth in oncology and infectious disease assays. Pathology Lab benefited from continued companion diagnostic adoption, including the July FDA approval of the Ventana PTEN RxDx Assay for prostate cancer, the first companion diagnostic to assess PTEN protein.

Near Patient Care was the softer line. Roche does not disclose year-over-year growth by customer area at H1, but the company’s aggregate commentary and the geographic breakdown point to that unit and to laboratory volume in China as the two segments carrying the drag.

China drag and the geographic picture

Asia-Pacific Diagnostics sales fell 5% at CER in H1 2026. The company continues to attribute the decline to volume-based procurement and centralised tendering in China, which have compressed pricing on assays and instruments across the region. The headwind is not new and Roche has not called an inflection.

Excluding China, Diagnostics grew 6% at CER, roughly matching the group. That figure is meaningful because it removes a policy shock that is not correlated with underlying diagnostic demand. It also aligns with what peers have reported for 2026 so far: Revvity called out China immunodiagnostics as a persistent drag and announced a letter of intent to sell that business for up to USD 200 million in May, and multiple IVD-adjacent names have flagged the same policy pressure in their Q1 and Q2 releases.

Roche’s ex-China number is therefore useful less as a forecast than as a shape of the underlying market. Reported figures still take the currency and pricing hit; underlying demand for immunodiagnostics, molecular assays, and companion diagnostics is not the driver of the reported softness.

Full-year outlook and near-term catalysts

The reaffirmed 2026 outlook - mid single digit group sales growth at CER, high single digit core EPS growth at CER, and a further dividend increase in Swiss francs - assumes no material change to the China pricing environment in the second half. Roche did not raise, but reaffirming after a 2% CHF top-line decline is itself a signal about the underlying trajectory.

Near-term Diagnostics catalysts flagged in the H1 materials:

  • The rollout of Axelios 1, the group’s next-generation sequencing platform built on SBX chemistry, which begins commercialisation in the second half of 2026.
  • Recent EU CE mark approvals for the Elecsys pTau217 blood test for Alzheimer’s pathology and the Elecsys IGRA TB test for latent tuberculosis, both of which target high-volume immunodiagnostic run rates on installed Core Lab systems.
  • Continued ramp of companion diagnostics on the Ventana platform, including the newly approved PTEN RxDx.

None of these are Q3 revenue events on their own. They are the pipeline that underwrites the ex-China growth rate through 2027.

What it signals for the analytics-vendor read

For readers who follow analytical instrumentation alongside IVD, three points from the print carry across:

China is a segment story, not a market story. Ex-China Diagnostics grew at 6% CER, in line with what Waters, Agilent, and Thermo Fisher have described for their diagnostic and pharma end markets outside of China in recent quarters. The China drag is real, but it does not appear to be spreading.

Immunodiagnostic run-rate demand held up. Roche called out immunodiagnostics and clinical chemistry as growth drivers in H1. That matters for instrument vendors whose consumables and assays run on installed Core Lab platforms, and it suggests that the Q1 signals from Revvity and the H1 2026 mid-year roundup - that laboratory volume is stable ex-China - continue to hold.

Currency does not travel to peers evenly. Roche’s 8-point spread between CER and CHF top-line growth is a Swiss franc issue, not a market issue. Peers reporting in USD or EUR see different translation effects. For side-by-side reading, use CER for Roche and reported growth for USD reporters, and take out FX in both directions before comparing to Q1 2026 vendor releases such as Waters BD Biosciences first combined quarter.

The next scheduled read on Diagnostics is Roche’s Q3 2026 sales update in October, which is a top-line release only. The full margin picture arrives with the FY 2026 report in late January 2027.